HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden

Abstract The genetically engineered chimeric antigen receptor T cell (CAR‐T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR‐T cell products in patients with h...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Yue Huang, Qin Yu, Elaine Tan Su Yin, Guoqing Wei, Wenjun Wu, Alex H. Chang, He Huang, Yongxian Hu
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2022-06-01
Serija:	ImmunoMedicine
Teme:	acute lymphoblastic leukemia allogeneic chimeric antigen receptor T cells central nervous system leukemia cytokine release syndrome HLA‐matched
Online dostop:	https://doi.org/10.1002/imed.1032
Oznake:	Označite Brez oznak, prvi označite!